⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019

Official Title: Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019

To assess the pharmacokinetics (PK), safety, and tolerability of fixed dose combination abacavir (ABC)/ dolutegravir (DTG)/ lamivudine (3TC) in HIV-1-infected children.

ClinicalTrials.gov ID: NCT03016533

Principal Investigator: Chadwick, Ellen G., MD

Study Type: Interventional

Currently Recruiting Patients: Yes

Contact Information:

Lela Lartey

Nurse Coordinator Research

312.227.8266